Клиническая инерция в терапии сахарного диабета 2 типа


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Обосновывается необходимость интенсификации терапии для улучшения гликемического контроля у больных сахарным диабетом 2 типа (СД2) и уменьшения риска диабетических осложнений. К сожалению, клиническая инерция или тенденция придерживаться выбранного курса лечения независимо от результатов, требующих интенсификации терапии, значительно снижает эффективность терапии пациентов с СД2. Рассматриваются возможности преодоления клинической инерции с помощью использования ингибитора дипептидилпептидазы-4 вилдаглиптина. Это обусловлено тем обстоятельством, что при выраженной сахароснижающей активности препарат характеризуется низким риском гипогликемий, хорошей переносимостью, возможностью использования при нарушениях функций почек и печени. Преодоление многофакторной природы клинической инерции требует усилий как от врачей, так и от пациентов. Появление эффективных и безопасных средств для лечения СД2 может оказать положительное влияние на готовность больных следовать врачебным рекомендациям, тем самым решая эту проблему.

Полный текст

Доступ закрыт

Об авторах

М. Б Анциферов

ГБУЗ «Эндокринологический диспансер» Департамента здравоохранения города Москвы

д.м.н., проф., глав. врач

Список литературы

  1. Allen J.D., Curtiss F.R., Fairman K.A. Nonadherence, clinical inertia, or therapeutic inertia? J. Manag. Care Pharm. 2009;15(8):690-95.
  2. Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr. Pract. 2011;17(Suppl. 2):1-53.
  3. Avignon A, Attali C, Sultan A., Ferrat E., Le Breton J. Clinical inertia: viewpoints of general practitioners and diabetologists. Diabetes Metab. 2012;38:S53-8.
  4. Berlowitz D.R., Ash A.S., Glickman M., Friedman R.H., Pogach L.M., Nelson A.L., Wong A.T. Developing a quality measure for clinical inertia in diabetes care. Health Serv. Res. 2005;40(6 Pt 1):1836-53.
  5. Bonds D.E., Miller M.E, Bergenstal R.M., Buse J.B., Byington R.P., Cutler J.A., Dudl R.J., Ismail-Beigi F., Kimel A.R., Hoogwerf B., Horowitz K.R, Savage P.J., Seaquist E.R., Simmons D.L., Sivitz W.I., Speril-Hillen J.M., Sweeney M.E. The association between symptomatic, severe hypo-glycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD studyy. Br. Med. J. 2010;340:b4909.
  6. Broadbent E, Donkin L., Stroh J.C. Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients. Diabetes Care. 2011; 34:338-40.
  7. Byrnes P.D. Why haven't I changed that? Therapeutic inertia in general practice. Aust. Fam. Physician. 2011;40(1-2):24-8.
  8. Calvert M.J., McManus R.J., Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br. J. Gen. Pract. 2007;57:455-60.
  9. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-24.
  10. Dang S., Sanchez A., Oropesa L., Roos B.A., Florez H. Telehealth-assisted care coordination of older veterans with type 2 diabetes lowers coronary heart disease risk despite clinical inertia. Diabetes Technol. Ther. 2010; 12(12):995-1001.
  11. Funnell M. Beyond the data: moving towards a new DAWN in diabetes. Diabet. Med. 2013;30:765-66.
  12. Garcia-Perez L.E., Alvarez M., Dilla T., Gil-Guillen V., OrozcoBeltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175-94.
  13. Giugliano D., Esposito K. Clinical inertia as a clinical safeguard. JAMA. 2011;305(15):1591-92.
  14. Goderis G., Borgermans L., Heyrman J., Broeke C.V., Grol R., Boland B., Mathieu C. Type 2 diabetes in primary care in belgium: need for structured shared care. Exp. Clin. Endocrinol. Diabetes. 2009;117(8):367-72.
  15. Grant R.W., Cagliero E., Dubey A.K., Gildes-game C., Chueh H.C., Barry M.J., Singer D.E., Nathan D.M., Meigs J.B. Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet. Med. 2004;21:150-55.
  16. Guthrie B., Inkster M., Fahey T. Tackling therapeutic inertia: role of treatment data in quality indicators. BMJ. 2007;335(7619):542-44.
  17. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10 Year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359:1577-89.
  18. Holt R.I., Nicoluci A., Kovacs Burns K., Escalante M., Forbes A., Hermanns N., Kalra S., Massi-Benedetti M., Mayorov A., Menendez-Torre E., Munro N., Skovlund S.E., Tarkun I., Wens J., Peyrot M.; DAWN2 Study Group. Diabetes Attitudes, Wishes and Needs second study (DAWN2): cross-national comparisons on barriers and resources for optimal care-health-care professional perspective. Diabet. Med. 2013;30:789-98.
  19. Home P., Naggar N.E., Khamseh M, Gonzalez-Galvez G., Shen C., Chakkarwar P., Wenying Y. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res. Clin. Pract. 2011;94:352-63.
  20. International Diabetes Federation. Global guideline for type2 diabetes. Diabetes Res Clin Pract 2014. http://dx.doi.org/ 10.1016/j.dia-bres.2012.10.001.
  21. Inzucchi S.E., Bergenstal R.M., Buse J.B, Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-96.
  22. Ishii H., Iwamoto Y., Tajima N. An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes And Needs (DAWN) Japan study. PLoS One. 2012;7(6):e36361.
  23. Khunti K., Gray L.J, Skinner T., Carey M.E, Realf K., Dallosso H., Fisher H., Campbell M., Heller S., Davies M.J. Effectiveness of a diabetes education and self managementprogramme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. Br. Med. J. 2012;344:e2333.
  24. Khunti K., Wolden M.L., Thorsted B.L., Ander-san M., Davies M.J. Clinical Inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411-17.
  25. Lovshin J.A., Zinman B. Diabetes Clinical inertia -a barrier to effective management of T2DM. Nat. Rev. Endocrinol. 2013;9:635-36.
  26. Nichols G.A., Koo Y.H., Shah S.N. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J. Gen. Intern. Med. 2007;22:453-8.
  27. Nicolucci A., Rossi M.C. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed. 2008;79(3):184-91.
  28. Oh S.W., Lee H.J., Chin H.J., Hwang J.I. Adherence to clinical practice guidelines and outcomes in diabetic patients. Int. J. Qual. Health Care. 2011;23(4):413-19.
  29. Phillips L.S., Branch W.T., Cook C.B., Doyle J.P., El-Kebbi I.M.,Gallina D.L.,Miller C.D.,Ziemer D.C., Barnes C.S. Clinical inertia. Ann. Intern. Med. 2001;135:825-34.
  30. Redon J., Coca A., Lazaro P., Aguilar M.D., Cabanas M., Gil N., Sanchez-Zamorano M.A., Aranda P. Factors associated with therapeutic inertia in hypertension: validation of a predictive model. J. Hypertens. 2010;28(8):1770-77.
  31. Rosenbek Minet L.K., Wagner L., Lonvig E.M., Hjelmborg J., Henriksen J.E. The effect of motivational interviewing on glycaemic control and perceived competence of diabetes self-management in patients with type 1 and type 2 diabetes mellitus after attending a group education programme: a randomised controlled trial. Diabetologia. 2011;54:1620-29.
  32. Ross S.A. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am. J. Med. 2013;126:S38-48.
  33. Scain S.F., Friedman R., Gross J.L. A structured educational program improves metabolic control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Educ. 2009;35:603.
  34. Steinsbekk A., Rygg L.O., Lisulo M., Rise M.B., Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv. Res. 2012;12:213.
  35. Strain W.D., Lukashevich V., Kothny W., Hoellinger M.J., Paldanius P.M. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, doubleblind, placebo-controlled study. Lancet. 2013;382:409-16.
  36. Strain W.D., Cos X., Hirst M., Vencio S., Mohan V., Voko Z, Yabe D., Bluher M, Paldanius P.M. Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2014; 105(3):302-12.
  37. Sutton E, Wilson H, Kaboli P.J., Carter B.L. Why physicians do not prescribe a thiazide diuretic. J. Clin. Hypertens. 2010;12(7):502-7.
  38. Valensi P., Benroubi M., Borzi V., Gumprecht J., Kawamori R., Shaban J., Shah S., Shestakova M., Wenying Y.; IMPROVE Study Group Expert Panel. The IMPROVE study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int. J. Clin. Pract. 2008;62:1809-19.
  39. Virkamaki A, Saltevo J. Finnish Current Care Guideline for Diabetes: interactive approach to improve individualized treatment. Diabetologia. 2011;54:1264-65.
  40. Wagner E.H., Sandhu N., Newton K.M., McCulloch D.K., Ramsey S.D., Grothaus L.C. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285(2):182-89.
  41. Wang T.J., Vasan R.S. Epidemiology of uncontrolled hypertension in the United States. Circulation. 2005;112(11):1651-62.
  42. Willig J.H., Jackson D.A., Westfall A.O., Allison J., Chang P.W, RaperJ., Saag M.S., Mugavero M.J. Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV clinic. Clin. Infect. Dis. 2008;46(8):1315-18.
  43. Yoshioka N., Ishii H., Tajima N., Iwamoto Y.; The DAWN Japan group. Differences in physician and patient perceptions about insulin therapy for management of type 2 diabetes: the DAWN Japan study. Curr. Med. Res. Opin. 2014;30(2):177-83.
  44. Анциферов М.Б., Аметов А.С., Зилов А.В. Ингибиторы ДПП-4: сегодня и завтра. Чего мы ждем от инкретинстимулирующей терапии? Фарматека. 2012;7.
  45. Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи пациентам с сахарным диабетом, 6-й выпуск. М., 2013.
  46. Черникова Н.А., Анциферов М.Б. Роль и место гипогликемии в управлении сахарным диабетом 2 типа. Фарматека. 2013; 16:27-32.
  47. Schweizer A., Dejager S., Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes. Metab. 2009;11(8):804-12.
  48. Ligueros-Saylan M., et.al. Vildagliptin therapy is not associated with an increased risk of pancreatitis. (abs. 769) Diabetologia. 2009; 52(Suppl. 1):S303.
  49. Foley J., Hoffmann, Liguecos-Saylan, Schwei-zer A., Kothny W. Lack of vildagliptin effects on the immune system. (abs. 773) Diabetologia. 2009;52(Suppl. 1):S304-5.
  50. Kothny W., et.al. Hepatic safety profile of vildagliptin, a new DPP4 inhibitor for the treatment of T2D. (abs. 764) Diabetologia. 2009;52(Suppl. 1):S301.
  51. Schweizer A., et.al. Assessing the cardiovascular safety of vildagliptin: a meta- analysis of adjudicated cardiovascular and cerebrovascular events from a large Ph 3 population. (abs. 703) Diabetologia. 2009;52(Suppl. 1):S300.
  52. Dejager A., Schweizer A. Incretin therapies in the Management of Patients with T2DM and Renal impairment. Hosp. Pract. 2012;40(2):7-21.
  53. Инструкция по медицинскому применению препарата Галвус.
  54. Dailey G. Early and Intensive Therapy for Management of Hyperglycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes. Clin. Ther. 2011;33(6):665-78.
  55. Mendes A.B.V., Fitipaldi J.A.S., Neves R.C.S., Chacra A.R., Moreira E.D.Jr. Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6,671 adults with diabetes in Brazil. Acta Diabetol. 2010; 47:137-45.
  56. Ferrannini E.,Fonseca V., Zinman B.,Matthews D., Ahrеn B., Byiers S., Shao Q., Dejager S. Fifty-two-week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes. Metab. 2009;11(2):157-66.
  57. Ning G., Wang W., Li L., Ma J., Lv X., Yang M., Wang W., Woloschak M., Lukaschevich V., Kothny W. Vildagliptin as an Add-on Therapy to Insulin Improves Glycemic Control without an Increased Risk of Hypoglycemia: A Dedicated Asian Study, in a Predominantly Chinese Population. American Diabetes Association. Sunday General Poster Session. 2014;1058.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2015